Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07460765 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT07460765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07460765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
July 31, 2026
Completion date
April 30, 2031
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck, hnscc, squamous carcinoma, squamous carcinoma poorly differentiated, squamous cell cancer, squamous cell cancer of head and neck (scchn), squamous cell cancer of the head and neck, squamous cell carcinoma (scc), squamous cell carcinoma (scc) of the oral cavity, squamous cell carcinoma head and neck cancer (hnscc), squamous cell carcinoma mouth